Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Jul;103(7):2551-2556.
doi: 10.1007/s00277-024-05790-0. Epub 2024 May 10.

DNT cells mediate resistance to CAR-T cells therapy in a pediatric patient with relapsed and refractory B-ALL

Affiliations
Case Reports

DNT cells mediate resistance to CAR-T cells therapy in a pediatric patient with relapsed and refractory B-ALL

Ruotong Chen et al. Ann Hematol. 2024 Jul.

Abstract

Chimeric antigen receptor T (CAR-T) cells therapy is a milestone achievement in the immunotherapy of relapsed and refractory (R/R) B cell acute lymphoblastic leukemia (B-ALL). However, some patients treated with CAR-T cells do not achieve complete remission, the mechanisms of which have not been elucidated. In the present study, we report a 9-year-old pediatric patient with refractory B-ALL received a triple infusion of autologous CD19 CAR-T cells therapy after the second relapse. CAR-T cells expanded in the peripheral blood and bone marrow. However, the patient did not achieve complete remission, indicating a lack of response to CAR-T cells therapy. Analysis of etiological factors revealed that the number of CD4 and CD8 double-negative T (DNT) cells was significantly upregulated in the peripheral blood, bone marrow, and autologous CAR-T cells products. In conclusiont, these findings indicate that DNT cells mediated resistance to CAR-T cells therapy in this pediatric patient with R/R B-ALL.

Keywords: Acute lymphoblastic leukemia; CD4 and CD8 double-negative T cells; Chimeric antigen receptor T cells; Relapsed and refractory.

PubMed Disclaimer

Similar articles

References

    1. Bulliard Y, Andersson BS, Baysal MA, Damiano J, Tsimberidou AM (2023) Reprogramming T cell differentiation and exhaustion in CAR-T cells therapy. Journal of Hematology & Oncology 16(1):108. doi:https://doi.org0.1186/s13045-023-01504-7
    1. Gumber D, Wang LD (2022) Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion. Ebiomedicine 77:103941. https://doi.org/10.1016/j.ebiom.2022.103941 - DOI - PubMed - PMC
    1. Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D, Gooley TA, Cherian S, Chen X, Pender BS, Hawkins RM, Vakil A, Steinmetz RN, Schoch G, Chapuis AG, Till BG, Kiem H-P, Ramos JD, Shadman M, Cassaday RD, Acharya UH, Riddell SR, Maloney DG, Turtle CJ (2019) Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood 133(15):1652–1663. https://doi.org/10.1182/blood-2018-11-883710 - DOI - PubMed - PMC
    1. Liu Y, Liu G, Wang J, Zheng Z-Y, Jia L, Rui W, Huang D, Zhou Z-X, Zhou L, Wu X, Lin S, Zhao X, Lin X (2021) Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors. Sci Transl Med 13(586):51–91. https://doi.org/10.1126/scitranslmed.abb5191 - DOI
    1. Spiegel JY, Patel S, Muffly L, Hossain NM, Oak J, Baird JH, Frank MJ, Shiraz P, Sahaf B, Craig J, Iglesias M, Younes S, Natkunam Y, Ozawa MG, Yang E, Tamaresis J, Chinnasamy H, Ehlinger Z, Reynolds W, Lynn R, Rotiroti MC, Gkitsas N, Arai S, Johnston L, Lowsky R, Majzner RG, Meyer E, Negrin RS, Rezvani AR, Sidana S, Shizuru J, Weng W-K, Mullins C, Jacob A, Kirsch I, Bazzano M, Zhou J, Mackay S, Bornheimer SJ, Schultz L, Ramakrishna S, Davis KL, Kong KA, Shah NN, Qin H, Fry T, Feldman S, Mackall CL, Miklos DB (2021) CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med 27(8):1419–1431. https://doi.org/10.1038/s41591-021-01436-0 - DOI - PubMed - PMC

Publication types

MeSH terms

LinkOut - more resources